Biosimilar

AVITA Medical to Attend the 2020 BTIG Healthcare Conference

Retrieved on: 
Tuesday, March 3, 2020
Biotechnology, Health, Surgery, Medical devices, Life sciences, Articles, Biotechnology, Pharmaceutical industry, Avita Medical, Biosimilar, Biopharmaceutical, Medtech, Regenerative medicine

AVITA Medical (ASX: AVH) (NASDAQ: RCEL), a global regenerative medicine company, announced that management will attend the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from Wednesday, March 18, 2020 through Thursday, March 19, 2020 at The Cliff Lodge in Snowbird, Utah.

Key Points: 
  • AVITA Medical (ASX: AVH) (NASDAQ: RCEL), a global regenerative medicine company, announced that management will attend the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from Wednesday, March 18, 2020 through Thursday, March 19, 2020 at The Cliff Lodge in Snowbird, Utah.
  • Authorised for release by the Chief Financial Officer of Avita Medical Limited.
  • AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications.
  • AVITA Medicals patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin.

FTC, FDA to Hold Workshop on Promoting Competition in Markets for Biologics

Retrieved on: 
Tuesday, March 3, 2020
Life sciences, Articles, Biotechnology, Pharmaceutical industry, Biosimilar, Drugs, Biopharmaceutical, Food and Drug Administration

On March 9, 2020, the Federal Trade Commission and the Food and Drug Administration will co-sponsor a public workshop on promoting competition in biologics markets.

Key Points: 
  • On March 9, 2020, the Federal Trade Commission and the Food and Drug Administration will co-sponsor a public workshop on promoting competition in biologics markets.
  • The workshop will be held at the FDAs White Oak Campus in Silver Spring, Maryland and will also be webcast.
  • Workshop panelists will discuss the agencies efforts to support competition between biosimilars and reference biologics, discouraging false or misleading statements about biosimilars safety and efficacy, and deterring anticompetitive behaviors in the biologic marketplace.
  • Last month, the FTC and the FDA signed a joint statement promoting competition in markets for biologics.

FTC, FDA to Hold Workshop on Promoting Competition in Markets for Biologics

Retrieved on: 
Tuesday, March 3, 2020
Life sciences, Articles, Biotechnology, Pharmaceutical industry, Biosimilar, Drugs, Biopharmaceutical, Food and Drug Administration

On March 9, 2020, the Federal Trade Commission and the Food and Drug Administration will co-sponsor a public workshop on promoting competition in biologics markets.

Key Points: 
  • On March 9, 2020, the Federal Trade Commission and the Food and Drug Administration will co-sponsor a public workshop on promoting competition in biologics markets.
  • The workshop will be held at the FDAs White Oak Campus in Silver Spring, Maryland and will also be webcast.
  • Workshop panelists will discuss the agencies efforts to support competition between biosimilars and reference biologics, discouraging false or misleading statements about biosimilars safety and efficacy, and deterring anticompetitive behaviors in the biologic marketplace.
  • Last month, the FTC and the FDA signed a joint statement promoting competition in markets for biologics.

Biosimilars - 2 Day Seminar (London, United Kingdom - October 6-7, 2020) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 3, 2020
Biotechnology, Pharmaceutical, Health, Life sciences, Articles, Biotechnology, Pharmaceutical industry, Biosimilar, Drugs, Biopharmaceutical

A two-day seminar on the overview of biosimilars and how they differ from the original biological product.

Key Points: 
  • A two-day seminar on the overview of biosimilars and how they differ from the original biological product.
  • With some of the world's best-known biologics continuing to face patent expiration in the coming years, the biosimilar market is set for continued growth.
  • This seminar will provide you with a global overview of biosimilars and how they differ from the original biological product.
  • The programme will discuss the unique considerations of biosimilars as compared with small-molecule generics.

Global Biologics Market: Analysis By Product Type, Application Type, Product Pipeline, End User, By Region, By Country : Market Insight, Competition and Forecast

Retrieved on: 
Monday, March 2, 2020
Life sciences, Articles, Biotechnology, Biopharmaceutical, Vaccine, Monoclonal antibody, Biosimilar

The report analyses Biologics Market by Product Type (Vaccines, Monoclonal Antibodies, Recombinant Hormones/Proteins, Cellular & Gene based, Others).

Key Points: 
  • The report analyses Biologics Market by Product Type (Vaccines, Monoclonal Antibodies, Recombinant Hormones/Proteins, Cellular & Gene based, Others).
  • The report assesses the Biologics market By Application (Cancer, Rare and Auto-immune Diseases, Infectious Diseases, Others).
  • Also, the attractiveness of the market has been presented by Region, Product Type, Application and End User.
  • The report presents the analysis of Biologics market for the historical period of 2015-2019 and the forecast period of 2020-2025.

Coherus BioSciences Management to Present at the 40th Annual Cowen Healthcare Conference

Retrieved on: 
Wednesday, February 26, 2020
Recombinant proteins, Life sciences, Medicine, Branches of biology, Pegfilgrastim, Biosimilar, Filgrastim

REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that senior management will present at the 40th Annual Cowen Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that senior management will present at the 40th Annual Cowen Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m.
  • ET, being held in Boston.
  • Coherus is a leading biosimilar company that develops and commercializes its own high-quality therapeutics as well as those of others seeking capable access to the United States market.
  • Coherus commercializes UDENYCA (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA in the European Union.

Arecor Achieves Second License Milestone Payment From Global Pharmaceutical Partner

Retrieved on: 
Tuesday, February 25, 2020
Articles, Intellectual property law, Expense, Patent law, Royalty payment, License, Biosimilar

The first milestone was triggered in October 2017 following the signature of a license agreement between the parties.

Key Points: 
  • The first milestone was triggered in October 2017 following the signature of a license agreement between the parties.
  • In accordance with the license agreement, the partner has rights to further develop, manufacture and commercialise a novel, superior formulation of a biosimilar product, which was developed by Arecor using its proprietary Arestat platform.
  • Under the terms of the exclusive global, royalty bearing license, a second milestone payment has been duly triggered.
  • Sarah Howell, Chief Executive Officer of Arecor, said:"The achievement of this second license milestone with our valued partner is an important testament of our ability to develop differentiated formulations of existing products that meet clinical and regulatory requirements.

Catalent to Host Workshop Demonstrating Advantages of Integrated Biologics Development Solutions in London, U.K.

Retrieved on: 
Thursday, February 20, 2020
Life sciences, Articles, Biotechnology, Pharmaceutical industry, Catalent, Biopharmaceutical, Biosimilar

SOMERSET, N.J., Feb. 20, 2020 /PRNewswire-PRWeb/ --Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced it will host a one day workshop to demonstrate the benefits of an integrated biologics development strategy, titled, "Achieving Integrated Biologics Development: Challenges and How to Tackle Them".

Key Points: 
  • SOMERSET, N.J., Feb. 20, 2020 /PRNewswire-PRWeb/ --Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced it will host a one day workshop to demonstrate the benefits of an integrated biologics development strategy, titled, "Achieving Integrated Biologics Development: Challenges and How to Tackle Them".
  • To arrange a meeting with any of the attending Catalent experts at the event, contact Richard Kerns at NEPR - [email protected] .
  • Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates.
  • For more information on Catalent Biologics, visit http://www.catalent.com/biologics
    Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products.

Coherus BioSciences Announces New Employment Inducement Grants

Retrieved on: 
Thursday, February 20, 2020
Life sciences, Articles, Biosimilar, Biotechnology, Drugs, NASDAQ, Pegfilgrastim, Natural sciences

A Vice President was also granted an option to purchase 75,000 shares of the companys common stock, with a per share exercise price of $22.16, the closing trading price on the grant date.

Key Points: 
  • A Vice President was also granted an option to purchase 75,000 shares of the companys common stock, with a per share exercise price of $22.16, the closing trading price on the grant date.
  • The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the companys board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
  • Coherus is a leading biosimilar company that develops and commercializes its own high-quality therapeutics as well as those of others seeking capable access to the United States market.
  • Coherus commercializes UDENYCA (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA in the European Union.

Global Biosimilars Market to Reach ~US$ 21.1 bn by 2027, Role in Reducing Cost of Cancer Treatment Key to Growth: Transparency Market Research

Retrieved on: 
Thursday, February 20, 2020
Life sciences, Biotechnology, Articles, Biology, Biosimilar, Monoclonal antibody

The global Biosimilars Market is expected to reach a value of ~US$ 21.1 bn by the end of 2027 and is projected to garner a CAGR of ~23% during 20192027.

Key Points: 
  • The global Biosimilars Market is expected to reach a value of ~US$ 21.1 bn by the end of 2027 and is projected to garner a CAGR of ~23% during 20192027.
  • Of all the indications, oncology led the global market by holding the major share in 2018.
  • Growing number of monoclonal antibodies approved by the U.S. FDA for the treatment of cancer has bolstered prospects in the biosimilars market.
  • Companies intending to up their stakes in the biosimilars market have increased their efforts in reducing the cost of treatment for cancer patients by offering those biosimilars.